DFDavid Furfaro

David Furfaro

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


David Furfaro has a total of 170 co-authors. Here are the top co-authors by number of shared publications:

  • Annette Ilg

    Department of Emergency Medicine, Brigham and Women's Hospital, Boston, MA, United States of America

    2 shared publications
  • Ari Moskowitz

    Bronx Center for Critical Care Outcomes and Resuscitation Research, Montefiore Medical Center, the Bronx, NY; Division of Critical Care Medicine, Montefiore Medical Center, the Bronx, NY

    2 shared publications
  • Daniel Brodie

    Columbia University Irving Medical Center and New York-Presbyterian Hospital, New York City, New York

    2 shared publications
  • Margaret M. Hayes

    Beth Israel Deaconess Medical Center Division of Pulmonary, Critical Care and Sleep Medicine Boston, Massachusetts

    2 shared publications
  • Michelle Ng Gong

    Division of Critical Care Medicine, Division of Pulmonary Medicine, Department of Medicine, Epidemiology and Population Health, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA

    2 shared publications
  • Samuel B. Brusca

    Division of Cardiology University of California San Francisco San Francisco California USA

    2 shared publications

Latest Publications

  • Open Access

    Pulmonary thromboendarterectomy for chronic thromboembolic disease—a safe but incomplete picture

    by John Fountain, Alison Witkin, David Furfaro

    Pulmonary thromboendarterectomy for chronic thromboembolic disease—a safe but incomplete picture

  • Automated data extraction from electronic medical records for pragmatic clinical trials

    by Eduardo Messias Hirano Padrao, Anne Thu Nguyen, Kevin Nguyen, Ioana A. Sopuch, Alper Gulluoglu, Maria Alejandra Alape, Samantha Harrison, Adrian Wong, Mehrnaz Sadrolashrafi, Gabrielle Cozzi, et al.

    Data collection in randomized trials is expensive and labor intensive. With the rise in ongoing pragmatic trials, the use of electronic medical records (EMR) as a source of data has increased. Although potentially faster and cheaper, EMR use can lead to errors. Therefore, to ensure accurate data collection and to avoid systematic errors we performed a study comparing automated data extraction (ADE) with manual data extraction (MDE). We performed a retrospective cohort study to compare the accuracy of ADE using Structured Query Language with MDE by blinded physicians from our EMR. We tested the interrater agreement and intraclass correlation coefficient of clinical baseline data and outcomes of a random sample of 30 patients admitted to the ICU, on mechanical ventilation, requiring opioids for analgosedation for an upcoming pragmatic clinical trial. Key data compared included, but not limited to, patient’s demographics, laboratory and vital signs, daily morphine milligram equivalent (MME), days alive and free of mechanical ventilation, days alive and free of hospitalization, days alive and free of ICU, days alive and free of vasopressors, and death. Among 238 patients screened over 1-month period, 72 fulfilled inclusion criteria and 30 were randomly selected to be included in the evaluation. We blindly collected 1320 baseline data, 2160 categorical outcomes and 705 continuous outcomes for a total of 4185 data points. The intraclass correlation coefficient and the Cohen’s Kappa were perfect or almost perfect for all data, including outcomes such as daily MME, days alive and free of mechanical ventilation, days alive and free of ICU and days alive and free of hospital with p < 0.001. Among all rechecked data, the ADE was correct in 53 (77.9%) of cases, while MDE in 15 (22.1%). The inaccurate data collected by ADE accounted for 0.36% of the total data-points. The performance of ADE had almost perfect agreement for all outcomes and when rechecking for disagreements, it was more accurate than MDE.

  • Open Access

    Time to Therapy Activation and Initial Combination Therapy (TITANIC) for Patients With Pulmonary Arterial Hypertension

    by Cyrus Kholdani, Carly J. Paoli, Tyler Peck, Wenze Tang, Noah Schoenberg, Sumeet Panjabi, David Furfaro

    Patients with pulmonary arterial hypertension (PAH) experience long delays in diagnosis; however, little is known about the time between diagnosis and initiation of guideline‐recommended optimal treatment. Immediate therapy is imperative for optimizing patient outcomes, as much of the pulmonary vasculature has already deteriorated by the time of diagnosis. This study used real‐world U.S. data to investigate the time from the most recent right heart catheterization (RHC) to initiation of the first PAH‐specific treatment. Adults with PAH were identified in the Komodo Health database using claims for RHC, pulmonary hypertension diagnostic codes, and PAH medications (1/1/2016–4/1/2024). Time from RHC to medication dispensing was examined and categorized by initial treatment regimen (monotherapy, dual therapy, and triple therapy). Baseline characteristics and treatment patterns were assessed. Among 7952 patients, the median time from most recent RHC to first PAH medication was 43.0 days. Most patients (77.7%) initially received monotherapy, with 20.0% and 2.3% receiving upfront dual and triple therapy, respectively. Cardiac comorbidities were present in most patients (85.8%). Among 2965 (48.0%) upfront monotherapy users who added another treatment during follow‐up, the median time to dual therapy was 39 days. Of those who escalated to dual therapy, 567 (19.1%) eventually escalated to triple therapy, with a median time from dual therapy to triple therapy of 62 days. In real‐world practice, delays between PAH diagnosis and initiation of optimal therapy remain significant, and barriers to access should be addressed.


  • Multidisciplinary Approach to Early Mobility at an Academic Medical Center

    by Dimpi A. Patel, Shannon M. Stillwell, Sara E. Booth, Meredith A. Schofield, Anna E. Silverstein, Alyse M. Reichheld, Roberto J. Gonzalez, Brian J. McDonnell, Susy L. Carnevale, Jacqueline L. Joy, et al.

    Objectives: ICU-acquired weakness affects 50% of critically ill patients. Early mobility programs have been shown to improve functional status at hospital discharge, shorten duration of mechanical ventilation, prevent delirium, and reduce length of stay. Despite these benefits, early mobility is one of the most difficult parts of the ABCDEF bundle to incorporate into practice. This project sought to use a multidisciplinary intervention to improve mobility in the ICU. Design: Randomized, pragmatic design quality improvement study. Setting: Two ICUs at a large academic medical center between July 2023 and February 2024. Patients: Five hundred seventy-four ICU patients with 271 in the intervention ICU and 276 in the control ICU. Interventions: A multidisciplinary quality improvement initiative focused on increasing education, raising awareness, and addressing barriers. Measurements and Main Results: Our primary outcome was achievement of an intensity-specific mobility goal with nursing staff on a patient-day level. A difference-in-differences model was used to evaluate the association between the mobility intervention and mobility goal achievement. The percentage of daily mobility goals met increased from 48.6% pre-intervention to 65.4% post-intervention in the intervention ICU ( p < 0.001). There was no significant difference in daily mobility goal adherence between the intervention and control ICU pre-intervention, but post-intervention, the intervention ICUs adherence was significantly higher (65.4% vs. 43.0%; p < 0.001). After controlling for demographic, clinical, and ICU characteristics, the intervention ICU was 1.96 times more likely to reach the daily mobility goal on a patient-day level ( p = 0.017). There was no significant change in ICU length of stay, inpatient length of stay, discharge to home, or in-hospital mortality between patients treated in the intervention vs. control ICU. Conclusions: A multidisciplinary quality improvement initiative can improve adherence to daily mobility goals.

  • Open Access

    Causes of Death Among Patients Supported by Extracorporeal Membrane Oxygenation

    by Renata P. Lerner, Amira Mohamed, Annette Ilg, Raghu R. Seethala, Alison Witkin, Jerome Crowley, Anthony Carlese, Michelle Ng Gong, Iris Aimlin, Jen-Ting Chen, et al.


  • Open Access

    “Awake” Cannulation of Patients for Venovenous Extracorporeal Membrane Oxygen: An Analysis of the Extracorporeal Life Support Organization Registry

    by Amira Mohamed, Omar Md Saeed, Melissa Fazzari, Michelle Gong, Mayuko Uehara, Stephen Forest, Anthony Carlese, Marjan Rahmanian, Sammar Alsunaid, Ali Mansour, et al.

    IMPORTANCE: “Awake” cannulation for venovenous extracorporeal membrane oxygenation (ECMO), where patients remain spontaneously breathing without invasive mechanical ventilation during the cannulation procedure, may reduce lung injury from positive pressure ventilation and promote patient mobility. OBJECTIVES: To examine the association between “awake” cannulation for venovenous ECMO and patient outcomes. DESIGN, SETTING, AND PARTICIPANTS: Analysis of the prospectively collected by the multicenter Extracorporeal Life Support Organization registry. Patients 18 years old or older who were cannulated for venovenous ECMO between 2016 and 2022 were included. MAIN OUTCOMES AND MEASURES: Propensity score matching techniques were used to examine the association between the primary exposure of “awake” cannulation and the primary outcome of hospital mortality. RESULTS: This study analyzed data from 28,627 patients who received venovenous ECMO, including 797 (2.8%) who underwent awake cannulation. Patients undergoing awake cannulation were older (52.2 vs. 47.8 yr), had greater prevalence of chronic lung diseases (50.6% vs. 48.9%), and ischemic heart disease (4.3% vs. 2.7%) compared with those cannulated while receiving mechanical ventilation. Hospital survival to discharge was did not differ significantly between awake and nonawake cannulation groups after propensity score matching (2.4% increased rate of survival for patients cannulated awake; 95% CI, –1.7% to 6.4%; p = 0.26). CONCLUSIONS AND RELEVANCE: In this large, multicenter study, awake cannulation for venovenous ECMO was uncommon but increasingly used over time. Survival to hospital discharge was similar to patients cannulated while on mechanical ventilation. Future research should focus on identification of patient cohorts most likely to benefit from “”awake” cannulation.


  • Open Access

    Sequelae of Acute Pulmonary Embolism: From Post-Pulmonary Embolism Functional Impairment to Chronic Thromboembolic Disease

    by John H. Fountain, Tyler J. Peck, David Furfaro

    Among survivors of acute pulmonary embolism (PE), roughly half report persistent dyspnea, impaired functional status, and decreased quality of life. Post-pulmonary embolism syndrome (PPES) is a broad condition which has been increasingly recognized in recent years and may be due to post-pulmonary embolism functional impairment, chronic thromboembolic disease, or the most severe long-term complication of PE, chronic thromboembolic pulmonary hypertension. Despite guideline recommendations for appropriate follow-up for post-pulmonary embolism patients, PPES remains underrecognized and diagnostic testing underutilized. Patients with symptoms suggestive of PPES at follow-up should undergo a transthoracic echocardiogram to screen for the presence of pulmonary hypertension; additional testing, such as a ventilation/perfusion scan, right heart catheterization, and cardiopulmonary exercise testing may be indicated. The pathophysiology of post-pulmonary embolism syndrome is complex and heterogeneous. In chronic thromboembolic pulmonary hypertension, the pathophysiology reflects persistent pulmonary arterial thrombi and a progressive small vessel vasculopathy. In patients with chronic thromboembolic disease or chronic thromboembolic pulmonary hypertension, medical therapy, balloon pulmonary angioplasty, or pulmonary thromboendarterectomy should be considered, and in cases of chronic thromboembolic pulmonary hypertension, pulmonary thromboendarterectomy significantly improves mortality. In all causes of post-pulmonary embolism syndrome, rehabilitation is a safe treatment option that may improve quality of life.


  • Open Access

    Metabolomic profiling and prognostication in COVID-19 acute respiratory distress syndrome

    by David Furfaro, Xiaoyu Che, Wenhao Gou, Matthew J. Cummings, Nischay Mishra, Daniel Brodie, Thomas Briese, Oliver Fiehn, W. Ian Lipkin, Max R. O'DOnnell


  • Open Access

    The Management of Cardiogenic Shock From Diagnosis to Devices

    by Fatimah A. Alkhunaizi, Nikolhaus Smith, Samuel B. Brusca, David Furfaro


  • Artificial Intelligence in Medical Education

    by David Furfaro, Leo Anthony Celi, Richard M. Schwartzstein